IPHA - Innate Pharma S.A.
NASDAQ
->
Healthcare
->
Biotechnology
Marseille,
France
Type: Equity
IPHA price evolution
IPHA
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $19.8 | $55.56 | $49.09 | $38.35 |
| Inventory | ||||
| Total current assets | $111.59 | $148.01 | $144.46 | $139.83 |
| Long term investments | ||||
| Property, plant & equipment | $5.75 | $6.32 | $7.26 | $8.54 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $151.5 | $184.19 | $199.05 | $207.86 |
| Current liabilities | ||||
| Accounts payable | $15.87 | $17.02 | $12.28 | $20.91 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $38.22 | $39.64 | $37.67 | $41.34 |
| Long term debt | $68.47 | $75.99 | $84.84 | $93.14 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $122.7 | $132.29 | $141.19 | $153.71 |
| Shareholders' equity | ||||
| Retained earnings | -$361.3 | -$336.4 | -$327.53 | -$329.5 |
| Other shareholder equity | $0 | -$0 | ||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $103.76 | $136.79 | ||
| Short term investments | $16.08 | $14.85 | ||
| Net receivables | $55.56 | $31.02 | $13.47 | $21.81 |
| Inventory | ||||
| Total current assets | $148.01 | $139.83 | $138.26 | $173.45 |
| Long term investments | $39.88 | $38.93 | ||
| Property, plant & equipment | $6.32 | $8.54 | $10.17 | $11.69 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $153.04 | |||
| Total investments | ||||
| Total assets | $184.19 | $207.86 | $267.5 | $307.42 |
| Current liabilities | ||||
| Accounts payable | $17.02 | $13.67 | $14.73 | $20.73 |
| Deferred revenue | $12.91 | |||
| Short long term debt | $29.94 | $1.36 | ||
| Total current liabilities | $39.64 | $41.34 | $79.89 | $45.49 |
| Long term debt | $75.99 | $93.14 | $11.49 | $14.19 |
| Total noncurrent liabilities | $121.04 | |||
| Total debt | ||||
| Total liabilities | $132.29 | $153.71 | $160.06 | $151.45 |
| Shareholders' equity | ||||
| Retained earnings | -$336.4 | -$329.5 | -$272.21 | -$220.46 |
| Other shareholder equity | $0.46 | $0.35 | ||
| Total shareholder equity | $107.44 | $155.98 | ||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8.29 | $16.56 | $35.34 | $8.31 |
| Cost of revenue | ||||
| Gross Profit | $6.66 | $33.83 | $6.67 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $32.97 | $28.83 | $34.23 | $31.59 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.08 | $2.98 | $1.07 | $0.95 |
| Net income | ||||
| Net income | -$24.76 | -$9.29 | $1.72 | -$64.41 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $51.9 | $49.58 | $24.7 | $70.45 |
| Cost of revenue | $47 | $58.61 | ||
| Gross Profit | $46 | -$22.3 | $11.84 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $25.52 | $31.25 | ||
| Total operating expenses | $64.57 | $62.42 | $72.53 | $89 |
| Operating income | -$47.83 | -$18.55 | ||
| Income from continuing operations | ||||
| EBIT | -$47.83 | -$18.55 | ||
| Income tax expense | ||||
| Interest expense | $5.1 | $1.09 | -$0.31 | -$0.34 |
| Net income | ||||
| Net income | -$7.57 | -$58.1 | -$52.81 | -$63.98 |
| Income (for common shares) | -$52.81 | -$63.98 | ||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $0.93 | $20.63 | -$0.25 | $1.88 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$4.33 | -$1.97 | -$1.25 | -$1.83 |
| Effect of exchange rate | -$0.26 | $0.27 | $0.14 | -$0.43 |
| Change in cash and equivalents | -$0.62 | -$13.62 | -$12.81 | -$19.53 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$52.81 | -$63.98 | ||
| Operating activities | ||||
| Depreciation | $4.6 | $13.27 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$58.46 | -$51.77 | ||
| Investing activities | ||||
| Capital expenditures | -$0.93 | -$0.91 | ||
| Investments | -$3 | |||
| Total cash flows from investing | $20.63 | $1.88 | -$0.92 | -$13.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $26.63 | -$0.89 | ||
| Total cash flows from financing | -$1.97 | -$1.83 | $26.82 | -$1.18 |
| Effect of exchange rate | $0.27 | -$0.43 | -$0.48 | $0.22 |
| Change in cash and equivalents | -$13.62 | -$19.53 | -$33.04 | -$66.1 |
News
|
3 Promising Penny Stocks With Market Caps Under US$300M
Simply Wall St. · via Yahoo Finance
11 Dec 2024
|
|
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
Zacks via Yahoo Finance
10 Apr 2024
|
|
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance
22 Mar 2024
|
|
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
Zacks via Yahoo Finance
4 Jan 2024
|
|
15 Undervalued Defensive Stocks For 2024
Insider Monkey via Yahoo Finance
24 Dec 2023
|
|
7 Hot Growth Stocks Poised to Triple in 2023
InvestorPlace via Yahoo Finance
5 May 2023
|
|
ORIC's Christmas Present From Pfizer: A $25m Equity Stake (NASDAQ:ORIC)
Seeking Alpha
22 Dec 2022
|
|
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis
Zacks via Yahoo Finance
19 Dec 2022
|
|
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's...
Investing.com
19 Dec 2022
|
|
Innate, Sanofi ink licensing deal for NK cells
Market Watch
19 Dec 2022
|
Fundamentals
| Market cap | $145.04M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 81.03M |
| Revenue | $68.50M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$96.74M |
| Revenue Q/Q | -79.91% |
| Revenue Y/Y | N/A |
| P/E ratio | -1.50 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.12 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.19 |
|---|---|
| ROA | -52.11% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.92 |
| Quick ratio | N/A |